Pancreatic Cancer Experimental Treatment

The Clinical Trials database is a good source for information on experimental treatments on many diseases, including pancreatic cancer. There are currently more than 700 clinical trials on pancreatic cancer in progress. The ones below provide examples of these studies in different categories of pancreatic cancer treatment. More information can be found through the link in the Resources section below using the NCT identifiers given here.

Resectable Cancers

• A study of disease-free survival after treatment with HyperAcute Pancreatic Cancer Vaccine is recruiting patients. Search ClinicalTrials.gov using the code NCT0569387.

Unresectable Cancers

• ReataPharmaceuticals has an ongoing study but is not recruiting at this time on the safety and efficacy of "Gemcitabine and RTA 402 for Patients with Unresectable Pancreatic Cancer." Find this study using the identification number NCT00529113.

Metastatic Cancer

• Loyola University in Maywood, Illinois, is recruiting patients for experimental treatment using regulatory T-cell suppression by Ontak monoclonal antibody. NCT00726037 is the identifier for this study.

Radiotherapy

• The Fox Chase Cancer Center in Philadelphia is recruiting patients for an experimental treatment using "Low-dose fractionated radiotherapy in patients with locally advanced metastatic pancreatic cancer." The identifier is NCT NCT00761345.

Combined Therapies

• Combining chemotherapy and radiation therapy with cyclophosphamide vaccine is an experimental treatment option being studied through the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore. Look up NCT00727441 on ClincalTrials.gov.